OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 09:56 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Emmaus Life Sciences Stock (OTCMKTS:EMMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.01▼$0.0250-Day Range$0.02▼$0.0752-Week Range$0.01▼$0.09Volume150,110 shsAverage Volume100,139 shsMarket Capitalization$1.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Emmaus Life Sciences is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly sickle cell disease. Its main product, Endari, is an oral powder formulation of L-glutamine approved in the United States to reduce acute complications of sickle cell disease in adults and children aged 5 years and older. The U.S. Food and Drug Administration approved Endari in 2017. Emmaus has also pursued development and commercialization opportunities for its products in markets outside the United States.AI Generated. May Contain Errors. Read More Emmaus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreEMMA MarketRank™: 0.346053891395 of 5 starsEmmaus Life Sciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Emmaus Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emmaus Life Sciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emmaus Life Sciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Emmaus Life Sciences has been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently increased by 229.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmmaus Life Sciences does not currently pay a dividend.Dividend GrowthEmmaus Life Sciences does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.36 News SentimentEmmaus Life Sciences has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Emmaus Life Sciences this week, compared to 0 articles on an average week.Search Interest2 people have searched for EMMA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.42% of the stock of Emmaus Life Sciences is held by institutions.Read more about Emmaus Life Sciences' insider trading history. Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMMA Stock News HeadlinesEmmaus Life Sciences Reports Quarterly Financial ResultsNovember 18 at 8:05 PM | businesswire.comEmmaus Life Sciences Reports Delay in Quarterly FilingNovember 16 at 8:10 PM | tipranks.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 19 at 1:00 AM | OilPrice (Ad)Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into AfricaNovember 12, 2026 | finance.yahoo.comEmmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic CancerAugust 31, 2026 | businesswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026 | businesswire.comEmmaus Life Sciences Reports Annual Financial ResultsMarch 30, 2026 | businesswire.comEmmaus Life Sciences grants NeoImmuneTech Endari distribution rightsDecember 31, 2025 | msn.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0130 at the beginning of 2026. Since then, EMMA stock has increased by 76.9% and is now trading at $0.0230. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Friday, August, 14th. The company reported $0.02 earnings per share for the quarter. The firm earned $6.32 million during the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Tesla (TSLA), Bloom Energy (BE), CVS Health (CVS), Anavex Life Sciences (AVXL), FuelCell Energy (FCEL), Cassava Sciences (FLNA) and Jazz Pharmaceuticals (JAZZ). Company Calendar Last Earnings8/14/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees33Year Founded2000Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.49 million Net Margins-38.78% Pretax Margin-34.93% Return on EquityN/A Return on Assets-31.18% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.07 Sales & Book Value Annual Sales$12.45 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-0.03Miscellaneous Outstanding Shares70,190,000Free Float45,622,000Market Cap$1.61 million OptionableNot Optionable Beta11.25 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.